Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) traded down 7.4% during trading on Wednesday . The company traded as low as $16.26 and last traded at $16.32. 75,692 shares were traded during trading, a decline of 63% from the average session volume of 202,513 shares. The stock had previously closed at $17.63.
Analyst Upgrades and Downgrades
Separately, StockNews.com upgraded Pulse Biosciences to a "sell" rating in a research report on Friday, September 20th.
Read Our Latest Stock Report on PLSE
Pulse Biosciences Stock Down 4.5 %
The company has a market capitalization of $1.03 billion, a P/E ratio of -20.79 and a beta of 1.74. The business has a fifty day moving average price of $17.93 and a 200 day moving average price of $13.86.
Hedge Funds Weigh In On Pulse Biosciences
Institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in Pulse Biosciences by 28.8% during the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company's stock worth $7,379,000 after purchasing an additional 189,227 shares during the last quarter. Griffin Asset Management Inc. increased its holdings in Pulse Biosciences by 15.7% in the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company's stock valued at $2,616,000 after purchasing an additional 40,700 shares during the period. Westside Investment Management Inc. grew its holdings in Pulse Biosciences by 97.8% during the 2nd quarter. Westside Investment Management Inc. now owns 63,600 shares of the company's stock worth $712,000 after acquiring an additional 31,440 shares during the period. Bank of New York Mellon Corp grew its holdings in Pulse Biosciences by 23.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company's stock worth $570,000 after acquiring an additional 9,639 shares during the period. Finally, Inspire Investing LLC grew its stake in shares of Pulse Biosciences by 32.1% in the 1st quarter. Inspire Investing LLC now owns 41,358 shares of the company's stock valued at $360,000 after buying an additional 10,039 shares during the period. Institutional investors and hedge funds own 76.95% of the company's stock.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Read More
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
